Teachers Advisors LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 990,514 shares of the biotechnology company’s stock after buying an additional 16,690 shares during the period. Teachers Advisors LLC owned 0.34% of Exelixis worth $21,464,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Swiss National Bank increased its position in shares of Exelixis by 18.4% in the first quarter. Swiss National Bank now owns 448,400 shares of the biotechnology company’s stock valued at $9,717,000 after buying an additional 69,700 shares during the period. Martingale Asset Management L P increased its position in shares of Exelixis by 5.9% in the first quarter. Martingale Asset Management L P now owns 59,428 shares of the biotechnology company’s stock valued at $1,288,000 after buying an additional 3,301 shares during the period. Atlantic Trust Group LLC bought a new position in shares of Exelixis during the first quarter valued at $216,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Exelixis by 14.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,751 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 1,838 shares during the period. Finally, Norges Bank bought a new position in shares of Exelixis during the fourth quarter valued at $36,882,000. Hedge funds and other institutional investors own 80.19% of the company’s stock.
Shares of Exelixis, Inc. (EXEL) traded up 1.91% during trading on Tuesday, reaching $27.20. The company had a trading volume of 3,102,076 shares. The stock’s 50-day moving average price is $25.47 and its 200-day moving average price is $21.97. Exelixis, Inc. has a 12 month low of $10.04 and a 12 month high of $28.45. The stock has a market capitalization of $7.99 billion, a PE ratio of 141.67 and a beta of 1.89.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The business had revenue of $99.01 million during the quarter, compared to analyst estimates of $85.27 million. During the same period in the prior year, the company posted ($0.15) EPS. The business’s revenue for the quarter was up 173.1% compared to the same quarter last year. Equities analysts forecast that Exelixis, Inc. will post $0.25 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Teachers Advisors LLC Buys 16,690 Shares of Exelixis, Inc. (NASDAQ:EXEL)” was posted by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://baseballnewssource.com/markets/exelixis-inc-nasdaqexel-shares-bought-by-teachers-advisors-llc-updated-updated-updated/1194559.html.
Several research analysts have weighed in on EXEL shares. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 target price on the stock in a research note on Tuesday, July 4th. Deutsche Bank AG downgraded Exelixis from a “buy” rating to a “hold” rating and lifted their target price for the company from $26.00 to $29.00 in a research note on Thursday, August 3rd. SunTrust Banks, Inc. began coverage on Exelixis in a research note on Thursday, July 13th. They issued a “buy” rating and a $33.00 target price on the stock. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Monday, June 26th. Finally, BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $25.57.
In other Exelixis news, insider Patrick J. Haley sold 5,000 shares of the stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total transaction of $92,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carl B. Feldbaum sold 32,988 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $21.58, for a total value of $711,881.04. Following the transaction, the director now directly owns 52,721 shares of the company’s stock, valued at $1,137,719.18. The disclosure for this sale can be found here. Insiders sold a total of 249,288 shares of company stock valued at $5,425,312 over the last three months. Corporate insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with our FREE daily email newsletter.